AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11035136 — intervention group
Group type: EXPERIMENTAL
Intervention: 4162W94 300 mg i.v. for 5 consecutive days
Number of subjects: 24
Study 11035136 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study 8622092 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release hydromorphone (IRH)
Number of subjects: 95
Study 8622092 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release hydromorphone (SRH)
Number of subjects: 95
Study 1599115 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG-9426 (600 micrograms/kg)
Number of subjects: 62
Study 1599115 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG-9426 (120 micrograms/kg)
Number of subjects: 62
Study 1599115 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG-9426 (240 micrograms/kg)
Number of subjects: 62
Study 3976556 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms Cr in the form of chromic chloride
Number of subjects: 76
Study 3976556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 31600343 — intervention group
Group type: EXPERIMENTAL
Intervention: ART at any CD4 cell count with enhanced support for ART and substance use treatment
Number of subjects: 449
Study 30025227 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal rehabilitation program (MRP) + usual care (UC)
Number of subjects: 32
Study 30025227 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 32
Study 27484880 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 5 mg/day
Number of subjects: 367
Study 27484880 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 1 mg/day or 10 mg/week
Number of subjects: 367
Study 27484880 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (both doses)
Number of subjects: 367
Study 22458386 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine-synthetic fiber socks
Number of subjects: 20
Study 22458386 — intervention group
Group type: COMPARATOR
Intervention: Cotton socks
Number of subjects: 20
Study 21750485 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (100 mcg/Kg b.w.)
Number of subjects: 21
Study 21750485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 20117669 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural auditory beats
Number of subjects: 20
Study 20117669 — intervention group
Group type: COMPARATOR
Intervention: Sham audio program (control)
Number of subjects: 20
Study 17941358 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics (including tetracyclines, subantimicrobial dose doxycycline, macrolides, trimethoprim-sulfamethoxazole, cephalosporins, and fluoroquinolones)
Number of subjects: 0
Study 17941358 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide
Number of subjects: 0
Study 17941358 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical and oral retinoids
Number of subjects: 0
Study 17941358 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 0
Study 15756901 — intervention group
Group type: EXPERIMENTAL
Intervention: Grommets intervention (specific dosage and duration not mentioned)
Number of subjects: 0
Study 15756901 — intervention group
Group type: COMPARATOR
Intervention: Prior beliefs of ENT‐surgeons (measured before the trial)
Number of subjects: 0
Study 11984098 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic therapy
Number of subjects: 11
Study 11984098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10456450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulphate (600 mg intramuscularly on the second day before surgery, then 300 mg once daily)
Number of subjects: 842
Study 10456450 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin (5,000 IU subcutaneously t.i.d., starting 2 hours before operation)
Number of subjects: 842
Study 10456450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulphate
Number of subjects: 842
Study 10456450 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin
Number of subjects: 842
Study 9407751 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise (>= 75% maximum heart rate)
Number of subjects: 42
Study 9407751 — intervention group
Group type: COMPARATOR
Intervention: Low intensity exercise (<= 60% maximum heart rate)
Number of subjects: 42
Study 1741875 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg secobarbital (S)
Number of subjects: 29
Study 1741875 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 micrograms/kg fentanyl (F)
Number of subjects: 29
Study 6284564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g die i.v. for 7 days
Number of subjects: 40
Study 6284564 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 240 mg die i.m. for 7 days
Number of subjects: 40
Study 31663156 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review with patient involvement (questionnaire and telephone call with pharmacist)
Number of subjects: 75
Study 31663156 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 75
Study 30706382 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐HRCT
Number of subjects: 10
Study 30706382 — intervention group
Group type: COMPARATOR
Intervention: C‐CT
Number of subjects: 10
Study 27453302 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic targeted- and immunotherapy (e.g., ipilimumab, pembrolizumab, nivolumab, vemurafenib, dabrafenib plus trametinib)
Number of subjects: 0
Study 27453302 — intervention group
Group type: COMPARATOR
Intervention: Interferon-2b
Number of subjects: 0
Study 26845668 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-weight suspension training
Number of subjects: 20
Study 26845668 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training
Number of subjects: 20
Study 24833694 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred consent process
Number of subjects: 17
Study 24833694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored explanation of EcLiPSE
Number of subjects: 17
Study 24833694 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety of interventions under investigation
Number of subjects: 17
Study 24833694 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment discussion timing
Number of subjects: 17
Study 24833694 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised approaches for bereaved parents
Number of subjects: 17
Study 24833694 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear written information
Number of subjects: 17
Study 23046985 — intervention group
Group type: EXPERIMENTAL
Intervention: Piece‐rate pay for performance (P4P) program
Number of subjects: 0
Study 23046985 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims analysis for younger adults
Number of subjects: 0
Study 23046985 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey study
Number of subjects: 0
Study 19897678 — intervention group
Group type: EXPERIMENTAL
Intervention: T(4) therapy
Number of subjects: 20
Study 18377908 — intervention group
Group type: EXPERIMENTAL
Intervention: Overhead ceiling lifts
Number of subjects: 0
Study 16153532 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional echocardiography (3DE)
Number of subjects: 100
Study 16153532 — intervention group
Group type: COMPARATOR
Intervention: M-mode echocardiography
Number of subjects: 100
Study 16153532 — intervention group
Group type: COMPARATOR
Intervention: 2-dimensional echocardiography (LA planimetry)
Number of subjects: 100
Study 16153532 — intervention group
Group type: COMPARATOR
Intervention: 2-dimensional echocardiography (prolate ellipsoid)
Number of subjects: 100
Study 16153532 — intervention group
Group type: COMPARATOR
Intervention: 2-dimensional echocardiography (area-length)
Number of subjects: 100
Study 16153532 — intervention group
Group type: COMPARATOR
Intervention: 2-dimensional echocardiography (Simpson's biplane)
Number of subjects: 100
Study 12109639 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of abciximab in full doses and reteplase in half doses
Number of subjects: 0
Study 12109639 — intervention group
Group type: COMPARATOR
Intervention: Reteplase in full doses
Number of subjects: 0
Study 10403324 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-dose regimen of artemether-lumefantrine (480 mg artemether and 2880 mg lumefantrine)
Number of subjects: 359
Study 10403324 — intervention group
Group type: COMPARATOR
Intervention: Four-dose regimen of artemether-lumefantrine (320 mg artemether and 1920 mg lumefantrine)
Number of subjects: 359
Study 7674841 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid human interferon alpha with prednisolone pretreatment (16 cases)
Number of subjects: 35
Study 7674841 — intervention group
Group type: COMPARATOR
Intervention: Lymphoblastoid human interferon alpha without prednisolone pretreatment (19 cases)
Number of subjects: 35
Study 7674841 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid human interferon alpha with or without prednisolone pretreatment
Number of subjects: 35
Study 1974510 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg/o.d.)
Number of subjects: 81
Study 1974510 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine (20 mg/o.d.)
Number of subjects: 81
Study 6155762 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 + H2-receptor antagonists (dimethypyrindene and cimetidine)
Number of subjects: 600
Study 6155762 — intervention group
Group type: COMPARATOR
Intervention: Haemaccel (control)
Number of subjects: 600
Study 6155762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine alone
Number of subjects: 600
Study 6155762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine plus chlorpheniramine
Number of subjects: 600
Study 31478283 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with a 660-nm diode laser (25 mW, fluence: 19.23 J/cm2) for three sessions
Number of subjects: 8
Study 31478283 — intervention group
Group type: COMPARATOR
Intervention: Sham laser (control)
Number of subjects: 8
Study 27834567 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Power
Number of subjects: 866
Study 27834567 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Power Plus
Number of subjects: 866
Study 27834567 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 866
Study 26683053 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer assessment
Number of subjects: 0
Study 26683053 — intervention group
Group type: COMPARATOR
Intervention: Control (no peer assessment)
Number of subjects: 0
Study 23005338 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress (Trier Social Stress Test; TSST)
Number of subjects: 38
Study 23005338 — intervention group
Group type: COMPARATOR
Intervention: Non-stressful control condition
Number of subjects: 38
Study 21107435 — intervention group
Group type: EXPERIMENTAL
Intervention: OM/HCTZ 40/25 mg
Number of subjects: 1172
Study 21107435 — intervention group
Group type: EXPERIMENTAL
Intervention: OM/HCTZ 40/12.5 mg
Number of subjects: 1172
Study 21107435 — intervention group
Group type: EXPERIMENTAL
Intervention: OM/HCTZ 20/12.5 mg
Number of subjects: 1172
Study 21107435 — intervention group
Group type: COMPARATOR
Intervention: OM 40 mg
Number of subjects: 1172
Study 18977314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (32 primary care practices)
Number of subjects: 56000
Study 18977314 — intervention group
Group type: COMPARATOR
Intervention: Control group (32 primary care practices)
Number of subjects: 56000
Study 18069643 — intervention group
Group type: EXPERIMENTAL
Intervention: Monolayer wide-edge continuous suture anastomosis with absorbable suture
Number of subjects: 936
Study 18069643 — intervention group
Group type: COMPARATOR
Intervention: Regular interrupted suture anastomosis with silk thread
Number of subjects: 936
Study 15084199 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct hemoperfusion with a beta2-microglobulin adsorption column (Lixelle)
Number of subjects: 22
Study 15084199 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pre-adsorption)
Number of subjects: 22
Study 11744588 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned Cesarean section at ≥38 weeks' gestation
Number of subjects: 2088
Study 11744588 — intervention group
Group type: COMPARATOR
Intervention: Planned vaginal birth by spontaneous labour unless an indication for induction or Cesarean section developed
Number of subjects: 2088
Study 9542676 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate emollient 0.05% twice daily (n = 41)
Number of subjects: 81
Study 9542676 — intervention group
Group type: COMPARATOR
Intervention: Emollient vehicle twice daily (n = 40)
Number of subjects: 81
Study 8001065 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel (1% applied 4 times a year, 0.7 ml applied interdentally)
Number of subjects: 117
Study 8001065 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (applied 4 times a year, 0.7 ml applied interdentally)
Number of subjects: 117
Study 8001065 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 117
Study 8001065 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel
Number of subjects: 117
Study 8001065 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 117
Study 8001065 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study 2086824 — intervention group
Group type: EXPERIMENTAL
Intervention: CEMT-PI-L (250 mg, 2 times a day)
Number of subjects: 103
Study 2086824 — intervention group
Group type: EXPERIMENTAL
Intervention: CEMT-PI-H (500 mg, 2 times a day)
Number of subjects: 103
Study 2086824 — intervention group
Group type: COMPARATOR
Intervention: CCL (500 mg, 3 times a day)
Number of subjects: 103
Study 2086824 — intervention group
Group type: EXPERIMENTAL
Intervention: CEMT-PI-L
Number of subjects: 103
Study 2086824 — intervention group
Group type: EXPERIMENTAL
Intervention: CEMT-PI-H
Number of subjects: 103
Study 2086824 — intervention group
Group type: COMPARATOR
Intervention: CCL
Number of subjects: 103
Study 146628 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical acne cream containing triclosan
Number of subjects: 3
Study 146628 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical acne cream containing triclosan plus propylene phenoxetol
Number of subjects: 3
Study 146628 — intervention group
Group type: COMPARATOR
Intervention: Control group (formula without antibacterials)
Number of subjects: 3
Study 31684758 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group (n = 18), structured, 12-week, progressive walking program 5 days/week for 12 weeks
Number of subjects: 33
Study 31684758 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (n = 15), usual activities
Number of subjects: 33
Study 31500505 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement quality-focused training (MQ)
Number of subjects: 46
Study 31500505 — intervention group
Group type: COMPARATOR
Intervention: Traditional resistance training (TRAD)
Number of subjects: 46
Study 27874023 — intervention group
Group type: COMPARATOR
Intervention: MAAT/placebo
Number of subjects: 71
Study 27874023 — intervention group
Group type: EXPERIMENTAL
Intervention: MAAT/MPH
Number of subjects: 71
Study 25468954 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) treatment with titration regimen, reduced to 2.5 mg daily after about 5 months, discontinued after 5 months (Group 1)
Number of subjects: 128
Study 25468954 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) treatment with titration regimen, reduced to 2.5 mg every other day after 5 months, discontinued after a further 5 months (Group 2)
Number of subjects: 128
Study 25468954 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with antithyroid drugs (ATD)
Number of subjects: 128
Study 23671210 — intervention group
Group type: EXPERIMENTAL
Intervention: Artiste Assisted Injection System
Number of subjects: 52
Study 23671210 — intervention group
Group type: COMPARATOR
Intervention: Manual delivery of dermal fillers
Number of subjects: 52
Study 20799296 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy
Number of subjects: 122
Study 20799296 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 122
Study 18543095 — intervention group
Group type: EXPERIMENTAL
Intervention: SABT intervention with manager training
Number of subjects: 980
Study 18543095 — intervention group
Group type: EXPERIMENTAL
Intervention: SABT intervention with combined peer/manager influence
Number of subjects: 980
Study 18543095 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 980
Study 18543095 — intervention group
Group type: EXPERIMENTAL
Intervention: SABT intervention (all types)
Number of subjects: 980
Study 18042885 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 selective inhibitors (e.g., rofecoxib, celecoxib)
Number of subjects: 0
Study 18042885 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective NSAIDs (e.g., diclofenac, naproxen)
Number of subjects: 0
Study 18042885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14742178 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance method
Number of subjects: 0
Study 14742178 — intervention group
Group type: COMPARATOR
Intervention: Display-size method combined with zero-slope criterion
Number of subjects: 0
Study 11890578 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week task-specific resistance-training intervention (training in bed- and chair-rise subtasks, such as sliding forward to the edge of a chair with the addition of weights)
Number of subjects: 161
Study 11890578 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week task-specific resistance-training intervention
Number of subjects: 161
Study 11890578 — intervention group
Group type: COMPARATOR
Intervention: Control flexibility intervention
Number of subjects: 161
Study 9425911 — intervention group
Group type: EXPERIMENTAL
Intervention: Variceal pressure (VP) measurement
Number of subjects: 87
Study 9425911 — intervention group
Group type: EXPERIMENTAL
Intervention: NIEC score + VP
Number of subjects: 87
Study 7843592 — intervention group
Group type: EXPERIMENTAL
Intervention: l-moprolol
Number of subjects: 27
Study 7843592 — intervention group
Group type: EXPERIMENTAL
Intervention: dipivefrin
Number of subjects: 27
Study 7843592 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of l-moprolol and dipivefrin
Number of subjects: 27
Study 3049116 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (TF) administered to 22 patients with Hodgkin's disease.
Number of subjects: 47
Study 3049116 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered to 25 patients with Hodgkin's disease (control group).
Number of subjects: 47
Study 31219281 — intervention group
Group type: EXPERIMENTAL
Intervention: STIC Initial Scales - Individual Problems and Strengths (IPS)
Number of subjects: 583
Study 31219281 — intervention group
Group type: EXPERIMENTAL
Intervention: STIC Initial Scales - Relationship with Partner (RWP)
Number of subjects: 583
Study 31219281 — intervention group
Group type: EXPERIMENTAL
Intervention: STIC Initial Scales - Family/Household (FH)
Number of subjects: 583
Study 31219281 — intervention group
Group type: EXPERIMENTAL
Intervention: STIC Initial Scales - Child Problems and Strengths (CPS)
Number of subjects: 583
Study 27744492 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture (group B)
Number of subjects: 45
Study 27744492 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin acetate (group A)
Number of subjects: 45
Study 27744492 — intervention group
Group type: COMPARATOR
Intervention: Combination of laser acupuncture and desmopressin (group C)
Number of subjects: 45
Study 25066831 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion for 30 min a day for five consecutive days
Number of subjects: 20
Study 25066831 — intervention group
Group type: COMPARATOR
Intervention: Control (unexposed forearm)
Number of subjects: 20
Study 23595003 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg/d (2000 IU/d, analysed dose 70 μg/d)
Number of subjects: 48
Study 23595003 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 μg/week (10 000 IU/week, analysed dose 331 μg/week)
Number of subjects: 48
Study 23595003 — intervention group
Group type: EXPERIMENTAL
Intervention: 1250 μg/week (50 000 IU/week, analysed dose 1544 μg/week) followed by 1250 μg/month
Number of subjects: 48
Study 23595003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 21636116 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab (75-375 mg, subcutaneously once every 2 or 4 weeks for 24 weeks)
Number of subjects: 49
Study 21636116 — intervention group
Group type: COMPARATOR
Intervention: placebo (subcutaneously once every 2 or 4 weeks for 24 weeks)
Number of subjects: 49
Study 21636116 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 49
Study 21636116 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 49
Study 19771409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal CPAP with open nostril
Number of subjects: 32
Study 19771409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal CPAP with occluded nostril
Number of subjects: 32
Study 19771409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal CPAP with closed mouth
Number of subjects: 32
Study 19771409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal CPAP with open mouth
Number of subjects: 32
Study 19771409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal CPAP with leaks <20%
Number of subjects: 32
Study 19771409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal CPAP with leaks between 20 and 69%
Number of subjects: 32
Study 16966225 — intervention group
Group type: EXPERIMENTAL
Intervention: Active abuse during pregnancy
Number of subjects: 35
Study 16966225 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaos, instability, and lack of resources
Number of subjects: 35
Study 15178174 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation (PA)
Number of subjects: 2
Study 15178174 — intervention group
Group type: COMPARATOR
Intervention: Neutral lenses (Control)
Number of subjects: 2
Study 11268375 — intervention group
Group type: COMPARATOR
Intervention: Vaccination with live attenuated rubella virus
Number of subjects: 0
Study 11268375 — intervention group
Group type: COMPARATOR
Intervention: LPS administration
Number of subjects: 0